Chronic Malignancies Working Party (CMWP)
Study type:
Study number:
42206698
Type of treatment:
Allogeneic
Allogeneic - Related
Diseases:
Multiple Myeloma (MM) or other Plasma Cell Disorder (PCD)
Short title:
Syngeneic HCT in MM
Primary objective:
The primary objective of this study is to evaluate the progression-free survival of patients with multiple myeloma undergoing syngeneic hematopoietic cell transplantation.
Key inclusion criteria:
All adult patients aged more than 18 years with multiple myeloma who received a syngeneic-HCT between 2000-2022.
Country:
All EBMT member countries
Principal investigator:
Iman Abou Dalle/Ibrahim Yakoub-Agha
EBMT Study coordinator:
Linda Koster
Study coordinator email:
cmwp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
DOB/YOB, gender
Medical data already reported to the EBMT Registry
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
No
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results